Cancer Prevention Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.canprevent.com
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Phase 2
Withdrawn
- Conditions
- Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms
- Interventions
- Drug: difluoromethylornithine
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Registration Number
- NCT01636128
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Phase 3
Completed
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT01483144
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Phase 3
Withdrawn
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Registration Number
- NCT01245816
© Copyright 2025. All Rights Reserved by MedPath